Cargando…
First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely
During the last 15 years, tremendous efforts have been made toward medical treatment of metastatic renal cell carcinoma (mRCC). Checkpoint inhibitors (CPI) and tyrosine kinase inhibitors (TKI) dominate the therapeutic armamentarium, as a combination of either CPIs or CPI/TKI, while the value of TKI...
Autores principales: | Ivanyi, Philipp, Wiegmann, Jonas Paul, Eggers, Hendrik, Grünwald, Viktor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427551/ https://www.ncbi.nlm.nih.gov/pubmed/37438555 http://dx.doi.org/10.1007/s12325-023-02571-5 |
Ejemplares similares
-
A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma
por: Ivanyi, Philipp, et al.
Publicado: (2023) -
Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis
por: Eggers, Hendrik, et al.
Publicado: (2017) -
Choosing Wisely in intensive care medicine
por: Lobo, Suzana Margareth, et al.
Publicado: (2020) -
Beyond the “Choosing wisely”: a possible attempt
por: Bernardini, Roberto, et al.
Publicado: (2016) -
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)